prikaz prve stranice dokumenta Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
  Preuzmi
PDF 3.06 MB
Znanstveni rad - Izvorni znanstveni rad
Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
Frontiers in Immunology, 13 (2022); 816159. https://doi.org/10.3389/fimmu.2022.816159
Ravlić, Sanda; Hećimović, Ana; Kurtović, Tihana; Ivančić Jelečki, Jelena; Forčić, Dubravko; Slović, Anamarija; Kurolt, Ivan Christian; Mačak Šafranko, Željka; Mušlin, Tatjana; Rnjak, Dina; Jakšić, Ozren; Sorić, Ena; Džepina, Gorana; Đaković Rode, Oktavija; Kujavec Šljivac, Kristina; Vuk, Tomislav; Jukić, Irena; Markotić, Alemka; Halassy, Beata Više autora...

Povezani objekti
COVID-19 | Virtualna zbirka

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Ravlić, S., Hećimović, A., Kurtović, T., Ivančić Jelečki, J., Forčić, D., Slović, A. ... Halassy, B. (2022). Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?. Frontiers in Immunology, 13.. doi: 10.3389/fimmu.2022.816159

Ravlić, Sanda, et al. "Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?." Frontiers in Immunology, vol. 13, 2022. https://doi.org/10.3389/fimmu.2022.816159

Ravlić, Sanda, Ana Hećimović, Tihana Kurtović, Jelena Ivančić Jelečki, Dubravko Forčić, Anamarija Slović, Ivan Christian Kurolt, et al. "Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?." Frontiers in Immunology 13 (2022). https://doi.org/10.3389/fimmu.2022.816159

Ravlić, S., et al. (2022) 'Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?', Frontiers in Immunology, 13. doi: 10.3389/fimmu.2022.816159

Ravlić S, Hećimović A, Kurtović T, Ivančić Jelečki J, Forčić D, Slović A, i sur.. Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?. Frontiers in Immunology [Internet]. 2022. [pristupljeno 22.11.2024.];13. doi: 10.3389/fimmu.2022.816159

S. Ravlić, et al., "Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?", Frontiers in Immunology, vol. 13, 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:917926. [Citirano: 22.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:917926
Podaci o radu
Naslov (engleski)Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
AutorSanda Ravlić
MBZ: 305793
AutorAna Hećimović
MBZ: 217216
AutorTihana Kurtović
MBZ: 309540
AutorJelena Ivančić Jelečki
MBZ: 238350
AutorDubravko Forčić
MBZ: 211105
AutorAnamarija Slović
MBZ: 380153
AutorIvan Christian Kurolt
MBZ: 302106
AutorŽeljka Mačak Šafranko
MBZ: 268386
AutorTatjana Mušlin
AutorDina Rnjak
AutorOzren Jakšić
MBZ: 238451
AutorEna Sorić
AutorGorana Džepina
AutorOktavija Đaković Rode
MBZ: 261522
AutorKristina Kujavec Šljivac
AutorTomislav Vuk
MBZ: 361422
AutorIrena Jukić
MBZ: 341464
AutorAlemka Markotić
AutorBeata Halassy
MBZ: 223834
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za zarazne bolesti)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
During the ongoing COVID-19 epidemic many efforts have gone into the investigation of the SARS-CoV-2–specific antibodies as possible therapeutics. Currently, conclusions cannot be drawn due to the lack of standardization in antibody assessments. Here we describe an approach of establishing antibody characterisation in emergent times which would, if followed, enable comparison of results from different studies. The key component is a reliable and reproducible assay of wild-type SARS-CoV-2 neutralisation based on a banking system of its biological components - a challenge virus, cells and an anti- SARS-CoV-2 antibody in-house standard, calibrated to the First WHO International Standard immediately upon its availability. Consequently, all collected serological data were retrospectively expressed in an internationally comparable way. The neutralising antibodies (NAbs) among convalescents ranged from 4 to 2869 IU mL-1 in a significant positive correlation to the disease severity. Their decline in convalescents was on average 1.4-fold in a one-month period. Heat-inactivation resulted in 2.3-fold decrease of NAb titres in comparison to the native sera, implying significant complement activating properties of SARS-CoV-2 specific antibodies. The monitoring of NAb titres in the sera of immunocompromised COVID-19 patients that lacked their own antibodies evidenced the successful transfusion of antibodies by the COVID-19 convalescent plasma units with NAb titres of 35 IU mL-1 or higher.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Immunology
Brojčani podacivol. 13, 816159
e-ISSN1664-3224
DOIhttps://doi.org/10.3389/fimmu.2022.816159
URN:NBNurn:nbn:hr:184:917926
Datum objave publikacije2022
ProjektŠifra: KK.011.1.01.0006
Naziv (hrvatski): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Voditelj: Stipan Jonjić
Pravna nadležnost: eu
Financijer: ERDF
ProjektŠifra: IP-CORONA-2020-04-2053
Naziv (hrvatski): Stvaranje preduvjeta za uvođenje SARS-CoV-2 seroterapije u Hrvatskoj
Voditelj: Beata Halassy
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: IP-CORONA
ProjektŠifra: N/A
Naziv (hrvatski): Centar izvrsnosti za virusnu imunologiju i cjepiva
Naziv (engleski): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Kratica: CERVirVac
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZCI
URL dokumentahttp://bib.irb.hr/1183053
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-03-23 11:02:26